Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037494 | 0.80 | NPSR1 (0.41) | PARP1 | |
| SCHEMBL6037528 | 0.78 | ALOX5 (0.42) | — | |
| SCHEMBL5804157 | 0.78 | TDP1 (0.41) | CA1CA2PARP10 | |
| SCHEMBL13871569 | 0.77 | RAB9A (0.42) | — | |
| SCHEMBL5404611 | 0.74 | PLAU (0.33) | — | |
| SCHEMBL11410329 | 0.72 | KDM4E (0.44) | — | |
| SCHEMBL28041937 | 0.71 | — | — | |
| SCHEMBL27450892 | 0.71 | GAA (0.35) | — | |
| SCHEMBL3117213 | 0.69 | — | — | |
| SCHEMBL23246120 | 0.69 | HCAR2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | claimed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | claimed |
| US-7671027-B2 | Use of GnRH agonists to support the luteal phase during infertility treatment | PREGLEM S.A. (CH) | 2010-03-02 | — | — | US | disclosed |
| US-7655658-B2 | Use of in the treatment of melanocortin receptor-associated disorders such as in treatment of anorexia, as a weight gain aid, for treatment of obesity | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1578427-B1 | USE OF GNRH AGONISTS TO SUPPORT THE LUTEAL PHASE DURING INFERTILITY TREATMENT | PREGLEM SA (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-7101868-B2 | Substituted arylamine derivatives and methods of use | AMGEN INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060069031-A1 | Use of gnrh agonists to support the luteal phase during infertility treatment | PREGLEM S.A. (CH) | 2006-03-30 | — | — | US | disclosed |
| EP-1578427-A1 | USE OF GNRH AGONISTS TO SUPPORT THE LUTEAL PHASE DURING INFERTILITY TREATMENT | Loumaye, Ernest (FR) | 2005-09-28 | — | — | EP | disclosed |
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004058269-A9 | USE OF GNRH AGONISTS TO SUPPORT THE LUTEAL PHASE DURING INFERTILITY TREATMENT | LOUMAYE ERNEST (FR) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004058269-A1 | USE OF GNRH AGONISTS TO SUPPORT THE LUTEAL PHASE DURING INFERTILITY TREATMENT | LOUMAYE ERNEST (FR) | 2004-07-15 | — | — | WO | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CA1 4831/4885CA2 4354/4885PARP1 1127/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CA1 4831/4885CA2 4354/4885PARP1 1127/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CA1 4831/4885CA2 4354/4885PARP1 1127/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CA1 4831/4885CA2 4354/4885PARP1 1127/4885 |
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | MC1R, MC5R, MC4R | CA1 4826/4885CA2 4333/4885PARP1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.